NASDAQ:SPRY ARS Pharmaceuticals Q2 2026 Earnings Report $5.36 +0.04 (+0.75%) Closing price 08/5/2026 04:00 PM EasternExtended Trading$5.30 -0.06 (-1.12%) As of 08/5/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast ARS Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.48Beat/MissN/AOne Year Ago EPSN/AARS Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$31.33 millionBeat/MissN/AYoY Revenue GrowthN/AARS Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateThursday, August 13, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile ARS Pharmaceuticals Earnings HeadlinesShareholder Notice: Robbins LLP Informs Investors of the ARS Pharmaceuticals Inc. Class Action2 hours ago | businesswire.comSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of ARS Pharmaceuticals, Inc. Securities and Sets a Lead Plaintiff Deadline of October 5, 2026August 5 at 5:43 PM | globenewswire.comIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this spring, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live. | Banyan Hill Publishing (Ad)ARS Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Strategic Update on August 13August 3 at 7:50 AM | quiverquant.comQARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial ResultsAugust 3 at 7:30 AM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYJuly 23, 2026 | prnewswire.comSee More ARS Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ARS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ARS Pharmaceuticals and other key companies, straight to your email. Email Address About ARS PharmaceuticalsARS Pharmaceuticals (NASDAQ:SPRY), a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.View ARS Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles SpaceX: Love the Company, But the Stock Is a Harder CallAMD’s Post-Earnings Drop May Be the Opportunity Investors WantedMeta’s Earnings Drop Shows Wall Street Wants More Than Ad GrowthUlta's Growth Is Real, But So Are the RisksBWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth StoryCoreWeave Powers Up: The Asia Infrastructure GrabPalantir Soars 30% After Blockbuster Earnings—Is the Rally Just Getting Started? Upcoming Earnings Airbnb (8/6/2026)Warner Bros. Discovery (8/6/2026)Monster Beverage (8/6/2026)Canadian Natural Resources (8/6/2026)ConocoPhillips (8/6/2026)Cheniere Energy (8/6/2026)Petroleo Brasileiro S.A.- Petrobras (8/6/2026)Targa Resources (8/6/2026)Aflac (8/6/2026)Howmet Aerospace (8/6/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
